Venture capital funding

UPS s entrepreneurial activities are driven by its venture capital fund and alliances with universities and partners. Here UPS understands that... 

Virtual pharma 4000- 5000 Venture capital funded, 1-2 developmental drugs, mainly biopharmaceuticals, small R D, no production, no M S organization Cell Therapeutics, Gilead, Trimeris, Vertex, USA Alizyme, UK Morphosys, Germany Actelion, Speedel, Switzerland... 

Ownership public private venture-capital funded family. 

Tate Lyle Ventures, a venture capital fund, and Scottish Enterprise s Scottish Venture Fund acquired BioFilm, Ltd. 

Value creation 11-21, 26-35 Value-driver trees 156, 159 Vendor managed inventory (VMI) 84 Ventro 34 Venture capital funds biotechnology 67, 77 corporate 117-118 innovation 32, 114 Venture capitalists 31, 66-67, 118 Vertical integration 37, 40-42 Vestolit 39 Victrex 98 Vinnolit 39 Virtual crackers 43 Virtual organization 122 Vopak 34, 35... 

The returns of the publicly-traded biotech venture capital funds - of which we found approximately ten - are comparable to the returns on an average venture capital fund. Fidelity Select Biotechnology, for example, recorded a 26.3 percent average annual return over a five-year period (Fig. 6.1). 

In the agrochemicals sector, where the application of biotechnology in chemical businesses is most advanced, the leading players have already demonstrated successful transformations along these lines that have led to a string of new ideas and new businesses key agrochemical players, for example, have set up corporate venture capital funds and created strong cooperations with startups. 

Corporate venture funds are venture capital funds financed pardy or entirely by industrial companies. They are ideally managed using the same financial criteria as venture capitalists would apply but, in addition, they have a strong relationship with their industrial investors. The startups funded then benefit from the investors industry knowledge, while the industrial investors not only receive a financial return but also better information from the market to use in external and internal investment decisions. They can provide access to new technologies and allow companies to build an external network by, for example, cooperating with a number of different startups. This has given some corporations access to important deals in return for a relatively small investment. 

After a long period of low activity, the commitment to corporate venture capital has increased sharply in recent years. The high-tech sector (including companies like Cisco Systems and Intel) has been enthusiastic about the idea, and corporate investment in US venture capital funds increased tenfold between 1995 and 1997 (Fig. 9.2). European chemical companies that are currently active in corporate venture capital include Bayer, Aventis, and BASF. 

Although, at the time of discovery FK 506 was reported as a new immunosuppressant agent being 100-fold more potent than cyclosporin A, efforts to displace cyclosporin A by FK 506, commercialized as tacrolimus, failed until today. It is worth mentioning that FK 506 stimulated the setup of the venture capital funded US company Vertex that aims at a designed drug to treat HIV infections starting from FK 506 as a lead compound. 

In the spring of 2000, nTouch Research doubled the size of its investigative site network when it acquired peer SMO Health Advance Medical Research. Having raised 8 million in venture capital funding only four months earlier, nTouch wasted no time in executing an aggressive expansion strategy. 

R D focused, one or two developmental drugs, no produetion, no marketing venture capital funded... 

Across the country, state governments have established economic development programs in many forms science and technology centers, seed and venture capital funds, business incubators, equipment subsidies, and even endowed university chairs. In 1988, 43 states were said to have spent 550 million on such programs. These state initiatives are strategic moves based on the premise that the application of scientific knowledge can be the basis for economic expansion and diversification as new businesses are created and old ones are made more competitive. 

In order to attract venture capital funding, it is often necessary to advance an overambitious development plan that requires far more money than is actually needed to launch the product. Aside from the issues of losing control of the business at too early a stage, such plans often lead to overruns in both costs and time to complete the market introduction of the product. 

Venture capital funding is normally based on excessive formal intellectual property (IP) portfolio development, which can increase costs, delay innovation and product launches in highly time-sensitive markets, as well as provide aggressive competitors with advance warning of new innovations coupled with the blueprints to copy them. 

Despite the deteriorating industrial and economic conditions, however. Plus 5 Pharmaceuticals was established in 1996. The start-up used venture capital funding (UNIDO, 2007 2011b), a testament to Zimbabwe s financial system s capability at the time, despite deindustrialization, and also to the continuing vibrancy of the pharmaceutical sector. The country continued to rely on locally manufactured medicines (Turshen, 2001), and Zimbabwe appears to have sustained some alignment of industrial and health policy goals through this tumultuous period. 

---